| 07/01/22 | Delisting of AS "Olainfarm” shares from the Baltic Main list | AQ |
| 06/01/22 | Notification about results of final buy-back of shares | AQ |
| 30/12/21 | Notification about final share buy-back | AQ |
| 28/12/21 | Correction: Regarding results of a share buy-back offer | AQ |
| 28/12/21 | On substantial participation (4) - specified | AQ |
| 1 day | +7.19% |
| Manager | Title | Age | Since |
|---|---|---|---|
Juris Hmelnickis
CEO | Chief Executive Officer | 46 | 31/12/2025 |
Janis Leimanis
DFI | Director of Finance/CFO | 56 | - |
| Chief Tech/Sci/R&D Officer | - | 31/12/2009 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 18/06/2021 | |
Janis Buks
CHM | Chairman | - | 31/08/2022 |
Roberts Tavjevs
BRD | Director/Board Member | - | - |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 04/08/21 | Sell | Chief Financial Officer | 97,424 | 0.6917% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +7.19% | +2.67% | - | - | 148M | |
| +0.12% | -3.33% | +35.53% | +111.51% | 1,019B | |
| -0.96% | -6.63% | +34.94% | +61.58% | 617B | |
| -0.33% | -1.72% | +13.69% | +77.49% | 464B | |
| -3.37% | -5.96% | +57.46% | +34.97% | 356B | |
| +0.48% | -2.42% | +20.25% | +40.58% | 333B | |
| -0.10% | -4.25% | +9.87% | +33.26% | 267B | |
| -1.00% | -5.83% | -7.56% | +7.91% | 244B | |
| -0.94% | -4.41% | +35.90% | +50.78% | 218B | |
| -0.64% | -5.84% | +26.18% | +91.85% | 179B | |
| Average | +0.04% | -3.54% | +25.14% | +56.66% | 410.8B | |
| Weighted average by Cap. | -0.60% | -3.54% | +28.30% | +68.13% |
Employees
2,191
Sector
Pharmaceuticals
